A study published in the Annals of Internal Medicine found that hospitalized COVID-19 patients who received therapeutic-dose anticoagulation with heparins had a lower 28-day mortality rate compared to those who received prophylactic-dose anticoagulation. The review, which included data from 20 trials and two additional studies, showed that higher-dose anticoagulation was associated with reduced mortality but increased risk of major bleeding. Patients who received therapeutic-dose anticoagulation also had fewer thromboembolic events. The study suggested that tailoring anticoagulation doses based on individual patient needs may improve outcomes for COVID-19 patients.
Source link
Therapeutic-dose anticoagulation linked to lower mortality in COVID-19
